Fisher B, Redmond C
National Surgical Adjuvant Breast and Bowel Project Headquarters, Pittsburgh, PA 15261.
J Natl Cancer Inst Monogr. 1992(11):7-13.
The data in this report continue to indicate, as first noted in 1985, that lumpectomy followed by breast irradiation in all patients, and adjuvant chemotherapy in women with positive nodes, is appropriate therapy for negative- or positive-node patients with tumors 4 cm or less in size, provided that the margins of the resected specimens are free of tumor. The value of irradiation in reducing the incidence of tumor in the ipsilateral breast after lumpectomy continues to be significant in all patients regardless of nodal status, age, or tumor size. A multivariate analysis indicates that, in all patients, three covariates, ie, treatment, tumors with poor histologic type, and tumors with a maximum pathologic size greater than or equal to 2 cm, are significant predictors of breast tumor recurrence following lumpectomy. Of particular significance is the continuing observation that the distant disease-free survival (DDFS) and survival (S) of patients in the three treatment groups (total mastectomy, lumpectomy alone, and lumpectomy followed by breast irradiation) demonstrate no significant difference through 9 years of follow-up, despite the fact that the total mastectomy group (by virtue of breast removal) had no breast tumor recurrence, that lumpectomy patients treated with breast irradiation had a 10% ipsilateral tumor recurrence, and that patients treated by lumpectomy alone demonstrated a 40% recurrence of tumor.(ABSTRACT TRUNCATED AT 250 WORDS)
本报告中的数据继续表明,正如1985年首次指出的那样,对于肿瘤大小在4厘米或以下的阴性或阳性淋巴结患者,所有患者均先进行肿块切除术,然后进行乳房照射,淋巴结阳性的女性进行辅助化疗,前提是切除标本的边缘无肿瘤。无论淋巴结状态、年龄或肿瘤大小如何,乳房照射在降低肿块切除术后同侧乳房肿瘤发生率方面的价值在所有患者中仍然显著。多变量分析表明,在所有患者中,三个协变量,即治疗、组织学类型差的肿瘤以及最大病理大小大于或等于2厘米的肿瘤,是肿块切除术后乳腺肿瘤复发的重要预测因素。特别重要的是持续观察到,三个治疗组(全乳房切除术、单纯肿块切除术以及肿块切除术后乳房照射)患者的远处无病生存率(DDFS)和生存率(S)在9年的随访中没有显著差异,尽管全乳房切除术组(由于切除了乳房)没有乳腺肿瘤复发,接受乳房照射的肿块切除术患者有10%的同侧肿瘤复发,而单纯接受肿块切除术的患者有40%的肿瘤复发。(摘要截短于250字)